Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents

• Verfasst von: Topaly, Julian [VerfasserIn]
• Verfasst von: Frühauf, Stefan [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Zeller, W. Jens [VerfasserIn]
• Titel: Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents
• Titelzusatz: implications for pretransplant conditioning
• Verf.angabe: J Topaly, S Fruehauf, A D Ho, W J Zeller
• Jahr: 2002
• Umfang: 7 S.
• Fussnoten: Gesehen am 13.01.2022
• Titel Quelle: Enthalten in: British journal of cancer
• Ort Quelle: Edinburgh : Nature Publ. Group, 1999
• Jahr Quelle: 2002
• Band/Heft Quelle: 86(2002), 9 vom: Mai, Seite 1487-1493
• ISSN Quelle: 1532-1827
• DOI: doi:10.1038/sj.bjc.6600242
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1785966987

Abstract

The tyrosine kinase activity of the BCR-ABL oncoprotein results in reduced apoptosis and thus prolongs survival of chronic myelogenous leukaemia cells. The tyrosine kinase inhibitor imatinib (formerly STI571) was reported to selectively suppress the proliferation of BCR-ABL-positive cells. Assuming that imatinib could be included in pretransplantation conditioning therapies, we tested whether combinations of imatinib and γ-irradiation or alkylating agents such as busulfan or treosulfan would display synergistic activity in BCR-ABL-positive chronic myelogenous leukaemia BV173 and EM-3 cell lines. Further, primary cells of untreated chronic myelogenous leukaemia patients were assayed for colony forming ability under combination therapy with imatinib. Additionally, the cytotoxic effect of these combinations on BCR-ABL-negative cells was investigated.